Jinhua

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Asthma7 trials
• COPD4 trials
• Chronic kidney disease2 trials
• Atrial fibrillation1 trial
• Bronchiectasis1 trial
• High blood pressure1 trial
• IgA nephropathy1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Ventricular tachycardia1 trial

Phase

• Phase 311 trials
• Phase 42 trials
• Phase 21 trial

Status

• Recruiting7 trials
• Completed6 trials
• Active, not recruiting2 trials
• Terminated1 trial

Lead sponsor

• AstraZeneca15 trials
• Alexion Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07774403· Phase 2· AstraZeneca· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China

  NCT06862206· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

  NCT06471257· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD3 recruiting
• Asthma2 recruiting
• Bronchiectasis1 recruiting
• Chronic kidney disease1 recruiting
• High blood pressure1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

  NCT06590740· Phase 4· AstraZeneca· Source

• Completed

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· Phase 3· AstraZeneca· Source

• Completed

  CARE FOR ALL：an Evaluation of an Asthma QIP

  NCT05440097· Phase 4· AstraZeneca· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source

• Completed

  Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

  NCT04536402· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· Phase 3· AstraZeneca· Source

• Completed

  Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

  NCT03927157· Phase 3· AstraZeneca· Source